Evercore Wealth Management LLC Buys Shares of 1,899 Quest Diagnostics Incorporated (NYSE:DGX)

Evercore Wealth Management LLC bought a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGXFree Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,899 shares of the medical research company’s stock, valued at approximately $262,000.

Other hedge funds have also added to or reduced their stakes in the company. Altshuler Shaham Ltd purchased a new stake in shares of Quest Diagnostics in the 4th quarter worth $26,000. BKM Wealth Management LLC purchased a new stake in shares of Quest Diagnostics in the 4th quarter worth $29,000. VisionPoint Advisory Group LLC increased its stake in shares of Quest Diagnostics by 100.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after purchasing an additional 109 shares in the last quarter. Alaska Permanent Fund Corp increased its stake in shares of Quest Diagnostics by 79.3% in the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock worth $33,000 after purchasing an additional 107 shares in the last quarter. Finally, MCF Advisors LLC increased its stake in shares of Quest Diagnostics by 179.8% in the 4th quarter. MCF Advisors LLC now owns 291 shares of the medical research company’s stock worth $40,000 after purchasing an additional 187 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Quest Diagnostics Stock Down 0.6 %

DGX opened at $141.47 on Tuesday. The firm has a 50-day simple moving average of $136.71 and a two-hundred day simple moving average of $133.55. Quest Diagnostics Incorporated has a 52 week low of $119.59 and a 52 week high of $145.62. The company has a market capitalization of $15.72 billion, a PE ratio of 19.04, a price-to-earnings-growth ratio of 3.09 and a beta of 0.90. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59.

Quest Diagnostics (NYSE:DGXGet Free Report) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.86 by $0.18. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The business had revenue of $2.37 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $2.04 EPS. The business’s revenue was up 1.7% on a year-over-year basis. Analysts forecast that Quest Diagnostics Incorporated will post 8.79 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 22nd. Stockholders of record on Monday, July 8th will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 2.12%. The ex-dividend date of this dividend is Monday, July 8th. Quest Diagnostics’s dividend payout ratio is 38.22%.

Analysts Set New Price Targets

Several research firms have recently commented on DGX. JPMorgan Chase & Co. upped their price objective on Quest Diagnostics from $152.00 to $155.00 and gave the stock a “neutral” rating in a research note on Thursday, May 30th. Citigroup upped their price objective on Quest Diagnostics from $135.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. SVB Leerink started coverage on shares of Quest Diagnostics in a report on Monday, February 26th. They issued a “market perform” rating and a $135.00 target price for the company. StockNews.com downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Friday. Finally, Barclays upped their target price on shares of Quest Diagnostics from $138.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Ten investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $146.67.

Get Our Latest Research Report on DGX

Insider Activity

In other news, SVP Karthik Kuppusamy sold 1,760 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $140.00, for a total transaction of $246,400.00. Following the sale, the senior vice president now directly owns 13,435 shares in the company, valued at approximately $1,880,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.79% of the company’s stock.

Quest Diagnostics Profile

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Stories

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.